Inflammatory bowel disease: Potential therapeutic strategies

Cytokines, Cellular and Molecular Therapy

Volumn 3, Issue 4, 1997, Pages 267-281

  Nielsen, Ole H ^a   Vainer, Ben ^a   Bregenholt, Søren ^b   Claësson, Mogens H ^b   Bishop, Paul D ^c   Kirman, Irena ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c R and D Department   (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Antibodies; Crohn's disease; Cytokines; Disease modulation; Factor XIII; Heparin; Immunology; Immunomodulation; Inflammation; Intestinal mucosa; Pharmacotherapeutics; Ulcerative colitis

Indexed keywords

1 [4 [N CHLOROACETYL N (2 ISOPROPOXYETHYL)AMINO]BENZOYL] 4 [2 (4 CHLOROPHENYL)ETHYL]PIPERAZINE; ALICAFORSEN; ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; AZATHIOPRINE; BLOOD CLOTTING FACTOR 13; CD4 ANTIGEN; CELL ADHESION MOLECULE; CYCLOSPORIN; G 124502X; GLUCOCORTICOID; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 15; ISIS 3082; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PENTOXIFYLLINE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG MECHANISM; ENTERITIS; HUMAN; HUMAN TISSUE; META ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CELL ADHESION MOLECULES; CYTOKINES; FACTOR XIII; HEPARIN; HUMANS; INFLAMMATORY BOWEL DISEASES; RECEPTORS, CYTOKINE;

EID: 0030697084     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (184)

1. Kornbluth A, Salomon P, Sachar DB, Crohn's disease. In: Gastrointestinal Disease, 5th edn (ed MH Sleisenger, JS Fordtran) 1271-304. WB Saunders, Philadelphia, 1993.
2. Sartor RB, Viewpoints on digestive diseases and cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology (1994) 106: 533-9.
3. Elsaser-Beile U, von Kleist S, Gerlach S et al, Cytokine production in whole blood cell cultures of patients with Crohn's disease and ulcerative colitis. J Clin Lab Anal (1994) 8: 447-51.
4. Autschbach F, Schrumann G, Qiao L et al, Cytokine messenger RNA expression and proliferation status of intestinal mononuclear cells in noninflamed gut and Crohn's disease. Virchows Arch (1995) 426: 51-60.
5. Reinecker HC, Steffen M, Witthoeft T et al, Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol (1993) 94: 174-81.
6. Sher ME, D'Angelo AJ, Stein TA et al, Cytokines in Crohn's colitis. Am J Surg (1995) 169: 133-6.
7. Woywodt A, Neustock P, Kruse A et al, Cytokine expression in intestinal mucosal biopsies. In situ hybridization of the mRNA for interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha in inflammatory bowel disease. Eur Cytokine Netw (1994) 5: 387-95.
8. Mitsuyama K, Toyonaga A, Sasaki E et al, IL-8 as an important chemoattractant for neutrophils in ulcera-tive colitis and Crohn's disease. Clin Exp Immunol (1994) 96: 432-6.
9. Mazzucchelli L, Hauser C, Zgaggen K et al, Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am J Pathol (1994) 144: 997-1007.
10. Duchmann R, Kaiser I, Hermann E et al, Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease. Clin Exp Immunol (1995) 102: 448-55.
11. Duchmann R, Schmitt E, Knolle P et al, Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol (1996) 26: 934-8.
12. Mosmann TR, Cherwinski H, Bond MW et al, Two types of murine helper T cell clone: I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 136: 2348-57.
13. Mosmann TR, Coffman RL, Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol (1989) 46: 111-47.
14. Street NE, Schumacher JH, Fong TA et al, Heterogeneity of mouse helper T cells. Evidence from bulk cultures and limiting dilution cloning for precursors of Th1 and Th2 cells. J Immunol (1990) 144: 1629-39.
15. Fiorentino DF, Bond MW, Mosmann TR, Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med (1989) 170: 2081-95.
16. Luscinskas FW, Brock AF, Arnaout MA, Gimbrone MA, Endothelial-leukocyte adhesion molecule-1-dependent and leukocyte (CD11/CD18)-dependent mechanisms contribute to polymorphonuclear leukocyte adhesion to cytokine-activated human vascular endothelium. J Immunol (1989) 142: 2257-63.
17. Kuijpers TW, Hakkert BC, Hoogerwerf M et al, Role of endothelial leukocyte adhesion molecule-1 and platelet-activating factor in neutrophil adherence to IL-1-prestimulated endothelial cell. J Immunol (1991) 147: 1369-76.
18. Donaldson LF, McQueen DS, Seckl JR, Neuropeptide gene expression and capsaicin-sensitive primary adderents: maintenance and spread of adjuvant arthritis in the rat. J Physiol (1995) 486: 473-82.
19. Neugebauer V, Rümenapp P, Schaible H-G, Calcitonin gene-related peptide is involved in the spinal processing of mechanosensory input from the rat's knee joint and in generation and maintenance of hyperexcitability of dorsal horn neurons during development of acute inflammation. Neuroscience (1996) 71: 1095-109.
20. Brattsand R, Concepts of topical steroid therapy. Res Clin Forums (1996) 18: 57-65.
21. Greenberg GR, Feagan BG, Martin F et al, Oral budesonide for active Crohn's disease. N Engl J Med (1994) 331: 836-41.
22. Sachar D, Budesonide for inflammatory bowel disease: Is it a magic bullet? N Engl J Med (1994) 331: 873-4.
23. Present DH, Korelitz BI, Wisch N et al, Treatment of Crohn's disease with 6-mercaptopurine. N Engl J Med (1980) 302: 981-7.
24. Sandborn WJ, Tremaine WJ, Cyclosporin treatment of inflammatory bowel disease. Mayo Clin Proc (1992) 67: 981-90.
25. Feagan BG, McDonald JWD, Rochon J et al, Low dose cyclosporin for the treatment of Crohn's disease. N Engl J Med (1994) 330: 1846-51.
26. Sartor RD, Editorial. N Engl J Med (1994) 330: 1897-8.
27. Feagan BG, Rochon J, Fedorak RN et al, Methotrexate for the treatment of Crohn's disease. N Engl J Med (1995) 332: 292-7.
28. Li YS, Wasserman R, Hayakawa K, Hardy RR, Identification of the earliest B lineage stage in mouse bone marrow. Immunity (1995) 5: 527-35.
29. Claesson MH, Rudolphi A, Koefoed S et al, CD4+ T lymphocytes injected into severe combined immunodeficient (SCID) mice lead to an inflammatory and lethal bowel disease. Clin Exp Immunol (1996) 104: 491-500.
30. Bregenholt S, Delbro D, Claesson MH, T cell transfer and TCR/cytokine gene deletion models in the study of inflammatory bowel disease. APMIS (1997) in press.
31. Davidson NJ, Leach MW, Fort MM et al, T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med (1996) 184: 241-51.
32. Simpson SJ, Mizoguchi E, Allen D et al, Evidence that CD4+, but not CD8+ T cells are responsible for murine interleukin-2-deficient colitis. Eur J Immunol (1995) 25: 2618-25.
33. Gulwani-Akolkar B, Akolkar PN, McKinley M et al, Crohn's disease is accompanied by changes in the CD4+, but not CD8+, T cell receptor BV repertoire of lamina propria lymphocytes. Clin Immunol Immunopathol (1995) 77: 95-106.
34. Gulwani-Akolkar B, Akolkar PN, Minassian A et al, Selective expansion of specific T cell receptors in the inflamed colon of Crohn's disease. J Clin Invest (1996) 98: 1344-54.
35. Probert CS, Chott A, Turner JR et al, Persistent clonal expansions of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease. J Immunol (1996) 157: 3183-91.
36. Hafler DA, Ritz J, Schlossman SF, Weiner HL, Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses. J Immunol (1988) 141: 131-8.
37. Hiepe F, Volk HD, Apostoloff E et al, Treatment of severe systemic lupus erythematosus with anti-CD4 monoclonal antibody. Lancet (1991) 338: 1529-30.
38. Choy EH, Chikanza IC, Kingsley GH, Panayi GS, Chimaeric anti-CD4 monoclonal antibody for relapsing polychondritis. Lancet (1991) 338: 450.
39. Mathieson PW, Cobbold SP, Hale G et al, Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med (1990) 323: 250-4.
40. Knox SJ, Levy R, Hodgkinson S et al, Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood (1991) 77: 20-30.
41. Thivolet J, Nicolas JF, Immunointervention in psoriasis with anti-CD4 antibodies. Int J Dermatol (1994) 33: 327-32.
42. Hahn HJ, Kuttler B, Laube F, Emmrich F, Anti-CD4 therapy in recent-onset IDDM. Diabet Metab Rev (1993) 9: 323-8.
43. Reinke P, Volk HD, Miller H et al, Anti-CD4 therapy of acute rejection in long-term renal allograft recipients. Lancet (1991) 338: 702-3.
44. Dantal J, Ninin E, Hourmant M et al, Anti-CD4 MoAb therapy in kidney transplantation - a pilot study in early prophylaxis of rejection. Transplantation (1996) 62: 1502-6.
45. Burmester GR, Emmrich F, Anti-CD4 therapy in rheumatoid arthritis. Clin Exp Rheumatol (1993) 11(Suppl8): S139-45.
46. Kalden JR, Anti-CD4 treatment of patients with rheumatoid arthritis. Is there still a place for this treatment principle in RA? Clin Exp Rheumatol (1994) 12(Suppl 11): S67-9.
47. Epstein WV, Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experience. Arthritis Rheum (1996) 39: 1773-80.
48. Murch SH, Walker-Smith JA, Medical management of chronic inflammatory bowel disease. Baillière's Clin Gastroenterol (1994) 8: 133-48.
49. Emmrich J, Seyfarth M, Fleig WE, Emmrich F, Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody. Lancet (1991) 338: 570-1.
50. Stronkhorst A, Radema S, Yong S-L et al, CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. Gut (1997) 40: 320-7.
51. Canva-Delcambre V, Jacquot S, Robinet E et al, Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody. Aliment Pharmacol Ther (1996) 10: 721-7.
52. Choy EH, Panayi GS, Kingsley GH, Therapeutic monoclonal antibodies. Br J Rheumatol (1995) 34: 707-15.
53. Choy EH, Adjaye J, Forrest L et al, Chimaeric anti-CD4 monoclonal antibody cross-linked by monocyte Fc gamma receptor mediates apoptosis of human CD4 lymphocytes. Eur J Immunol (1993) 23: 2676-81.
54. Rep MHG, van Oosten BW, Roos MTL et al, Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-γ secreting Th1 cells in humans. J Clin Invest (1997) 99: 2225-31.
55. Choy EH, Kingsley GH, Anti-CD4 therapy in rheumatoid arthritis. Clin Exp Rheumatol (1993) 11(Suppl 8): S147-9.
56. Kinne RW, Becker W, Schwab J et al, Imaging rheumatoid arthritis joints with technetium-99m labelled specific anti-CD4- and non-specific monoclonal antibodies. Eur J Nucl Med (1994) 21: 176-80.
57. Kinne RW, Becker W, Simon G et al, Joint uptake and body distribution of a technetium-99m labeled anti-rat CD4 monoclonal antibody in rat adjuvant arthritis. J Nucl Med (1993) 34: 92-8.
58. Center DM, Kornfield H, Cruikshank WW, Interleukin 16 and its function as a CD4 ligand. Immunol Today (1996) 10: 476-81.
59. Gaffney PR, Doyle CT, Gaffney A et al, Paradoxical response to heparin in 10 patients with ulcerative colitis. AmJ Gastroenterol (1995) 90: 220-3.
60. Gaffney PR, Gaffney A, Heparin therapy in refractory ulcerative colitis: an update. Gastroenterology (1996) 110(Suppl): A913.
61. Brazier F, Yzet T, Boruchowicz A et al, Treatment of ulcerative colitis with heparin. Gastroenterology (1996) 110(Suppl): A872.
62. Dupas JL, Brazier F, Yzet T et al, Treatment of active Crohn's disease with heparin. Gastroenterology (1996) 110(Suppl): A900.
63. Dobosz M, Mionskowska L, Dobrowolski S et al, Is nitric-oxide and heparin treatment justified in inflammatory bowel-disease -an experimental study. Scand J Clin Lab Invest (1996) 56: 657-63.
64. Dhillon AP, Anthony A, Sim R et al, Mucosal capillary thrombi in rectal biopsies. Histopathology (1992) 21: 127-33.
65. Wakefield AJ, Sawyerr AM, Dhillon AP et al, Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet (1989) ii: 1057-62.
66. Dwarakanath AD, Yu LG, Brookes C et al, 'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut (1995) 37: 585-8.
67. Thompson NP, Wakefield AJ, Pounder RE, Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology (1995) 108: 1011-15.
68. Talbot RW, Heppell J, Dozois RR, Beart RW Jr, Vascular complications of inflammatory bowel disease. Mayo Clin Proc (1986) 61: 140-5.
69. Hudson M, Chitolie A, Hutton RA et al, Thrombotic vascular risk factors in inflammatory bowel disease. Gut (1996) 38: 733-7.
70. Cerletti C, Rajtar G, Marchi E, de Gaetano G, Interaction between glycosaminoglycans, platelets, and leukocytes. Semin Thromb Hemost (1994) 20: 245-53.
71. Lucio J, D'Brot J, Guo CB et al, Immunologic mast cell-mediated responses and histamine release are attenuated by heparin. J Appl Physiol (1992) 73: 1093-101.
72. Tangelder GJ, Arfors KE, Inhibition of leukocyte rolling in venules by protamine and sulfated polysaccharides. Blood (1991) 77: 1565-71.
73. Bar-Ner M, Eldor A, Wasserman L et al, Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood (1987) 70: 551-7.
74. Walsh RL, Dillon TJ, Scicchitano R, McLennan G, Heparin and heparan sulphate are inhibitors of human leucocyte elastase. Clin Sci (Colch) (1991) 81: 341-6.
75. D'Argenio G, Biancone L, Cosenza V et al, Transglutaminases in Crohn's disease. Gut (1995) 37: 690-5.
76. Hudson M, Wakefield AJ, Hutton RA et al, Factor XIIIA subunit and Crohn's disease. Gut (1993) 34: 75-9.
77. Wisen O, Garlund B, Hemostasis in Crohn's disease: low factor XIII levels in active disease. Scand J Gastroenterol (1988) 23: 961-6.
78. Suzuki R, Toda H, Takamura Y, Dynamics of blood coagulation factor XIII in ulcerative colitis and preliminary study of the factor XIII concentrate. Blut (1989) 59: 162-4.
79. Stadnicki A, Kloczko J, Nowak A et al, Factor XIII subunits in relation to some other hemostatic parameters in ulcerative colitis. Am J Gastroenterol (1991) 86: 690-3.
80. Seitz R, Leugner F, Katschinski M et al, Ulcerative colitis and Crohn's disease: factor XIII, inflammation and haemostasis. Digestion (1994) 55: 361-7.
81. Van Bodegraven A, Tuynman HA, Schoorl M et al, Fibrinolytic split products, fibrinolysis, and factor XIII activity in inflammatory bowel disease. Scand J Gastroenterol (1995) 30: 580-5.
82. Lorenz R, Heinmuller M, Classen M et al, Substitution of factor XIII: a therapeutic approach to ulcerative colitis. Haemostasis (1991) 21: 5-9.
83. Oshitani N, Kitano A, Hara J et al, Deficiency of blood coagulation factor XIII in Crohn's disease. Am J Gastroenterol (1995) 90: 1116-18.
84. Lorenz R, Born P, Olbert P, Classen M, Factor XIII substitution in ulcerative colitis. Lancet (1995) 345: 449-50.
85. Oshitani N, Nakamura S, Matsumoto T et al, Treatment of Crohn's disease fistulas with coagulation factor XIII. Lancet (1996) 347: 119-20.
86. McDonagh J, Fukue H, Determinants of substrate specificity for factor XIII. Semin Thromb Hemost (1996) 22: 369-76.
87. Tosetto A, Castaman G, Rodeghiero F, Acquired plasma factor XIII deficiencies. Haematologica (1993) 78(Suppl 2): 5-10.
88. Aeshlimann D, Mosher D, Paulsson M, Tissue transglutaminase and factor XIII in cartilage and bone remodeling. Semin Thromb Hemost (1996) 22: 437-44.
89. Devine DV, Bishop PD, Platelet-associated factor XIII in platelet activation, adhesion and clot stabilization. Semin Thromb Hemost (1996) 22: 409-13.
90. Stief TW, Factor XIII of blood coagulation inhibits the oxidative phagocyte metabolism and suppresses the immune response in vivo. Thromb Res (1991) 63: 227-38.
91. Hirahara K, Shinbo K, Takahashi M, Matsuishi T, Suppressive effect of human blood coagulation factor XIII on the vascular permeability induced by antiguinea pig endothelial cell antiserum in guinea pigs. Thromb Res (1993) 71: 139-48.
92. Mishra L, Mishra BB, Harris M et al. In vitro cell aggregation and cell adhesion molecules in Crohn's disease. Gastroenterology (1993) 104: 772-9.
93. Vainer B, Horn T, Nielsen OH, Expression of E-selectin, sialyl Lewis X, and macrophage inflammatory protein-1α by colonic epithelial cells in ulcerative colitis. Dig Dis Sci (1997) submitted.
94. 1-integrin/matrix interactions in human colonic crypt cells. Gastroenterology (1996) 110: 1776-84.
95. Patel RT, Pall AA, Adu D, Keighley MR, Circulating soluble adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol (1995) 7: 1037-41.
96. Jones SC, Bankis RE, Haidar A, Adhesion molecules in inflammatory bowel disease. Gut (1995) 36: 724-30.
97. Goggins KG, Mahmud N, Keeling OWN et al. Elevated ICAM-1, VCAM-1 and E-selectin in active inflammatory bowel disease. Gastroenterology (1994) 106(Suppl): A690.
98. Goggins MG, Mahmud N, McDonald GS et al, Serum VCAM-1 reflects the grade of intestinal inflammation in patients with Crohn's disease. Gastroenterology (1995) 108(Suppl): A825.
99. Nielsen OH, Brynskov J, Vainer B, Increased mucosal concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin, and interleukin-8 in ulcerative colitis. Dig Dis Sci (1996) 41: 1780-5.
100. Schürmann GM, Aber-Bishop AE, Facer P et al, Altered expression of cell adhesion molecules in uninvolved gut in inflammatory bowel disease. Clin Exp Immunol (1993) 94: 341-7.
101. Schürmann GM, Bishop AE, Facer P et al, Increased expression of the cell adhesion molecule P-selectin in active inflammatory bowel disease. Gut (1995) 36: 411-18.
102. Morise K, Yamaguchi T, Kuroiwa A, Expression of adhesion molecules and HLA-DR by macrophages and dendritic cells in aphtoid lesions of Crohn's disease. An immunocytochemical study. J Gastroenterol (1994) 29: 257-64.
103. Nielsen OH, Langholz E, Hendel J, Brynskov J, Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease. Dig Dis Sci (1994) 39: 1918-23.
104. Nakamura S, Ohtani H, Watanabe Y et al, In situ expression of the cell adhesion molecules in inflammatory bowel disease: evidence of immunological activation of vascular endothelial cells. Lab Invest (1993) 69: 77-85.
105. Pooley N, Ghosh L, Sharon P, Up-regulation of E-selectin and intercellular adhesion molecule-1 differs between Crohn's disease and ulcerative colitis. Dig Dis Sci (1995) 40: 219-25.
106. Oshitani N, Campbell A, Bloom S et al, Adhesion molecules expression on vascular endothelium and nitroblue tetrazolium reducing activity in human colonic mucosa. Scand J Gastroenterol (1995) 30: 915-20.
107. Greenfield SM, Hamblin A, Pauchard NA, Thompson RPH, Expression of adhesion molecules on circulating leucocytes in patients with inflammatory bowel disease. Clin Sci (1992) 83: 221-6.
108. Kirman I, Nielsen OH, LFA-1 subunit expression in ulcerative colitis patients. Dig Dis Sci (1996) 41: 670-6.
109. Malizia G, Calabrese A, Cottone M et al, Expression of leukocyte mononuclear phagocytes in inflammatory bowel disease. Gastroenterology (1991) 100: 150-9.
110. Picarella D, Hurlbut P, Rottman J et al, Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 reduce inflammation in the colon of SCID mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol (1997) 158: 2099-106.
111. Podolsky DK, Lobb R, King N et al, Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest (1993) 92: 372-80.
112. Wong PY, Yue G, Yin K et al, Antibodies to intercellular adhesion molecule-1 ameliorate the inflammatory response in acetic acid-induced inflammatory bowel disease. J Pharmacol Exp Ther (1995) 247: 475-80.
113. Bennett CF, Stecker K, Cooper S, Howard, R, An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfatate sodium-induced colitis in mice. Gastroenterology (1997) 112: A931.
114. Yacyshyn B, Woloschuk B, Yacyshyn MB et al, Efficacy and safety of ISIS 2302 (ICAM-1 antisense oligonucleotide) treatment of steroid-dependent Crohn's disease. Gastroenterology (1997) 112: A1123.
115. Arend WP, Interleukin-1 receptor antagonist. Adv Immunol (1993) 54: 167-227.
116. Nishiyama T, Misuyama K, Toyonaga A et al, Colonic mucosal interleukin 1 receptor antagonist in inflammatory bowel disease. Digestion (1994) 55: 368-73.
117. Hyams JS, Fitzgerald JE, Wyzga N et al, Characterization of circulating interleukin-1 receptor antagonist expression in children with inflammatory bowel disease. Dig Dis Sci (1994) 39: 1893-9.
118. Hyams JS, Fitzgerald JE, Wyzga N et al, Relationship of interleukin-1 receptor antagonist to mucosal inflammation in inflammatory bowel disease. J Pediatr Gastroenterol Nutr (1995) 21: 419-25.
119. Casini-Raggi V, Kam L, Chong YJ et al, Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease: a novel mechanism of chronic intestinal inflammation. J Immunol (1995) 154: 2434-40.
120. Hendel J, Nielsen OH, Madsen S, Brynskov J, A simple filter-paper technique allows detection of mucosal cytokine levels in vivo in ulcerative colitis: interleukin-1 and interleukin-1 receptor antagonist. Dig Dis Sci (1996) 41: 1775-9.
121. Holt LC, Böcker U, Damiao A et al, Decreased ratio of IL-1RA/IL-1 mRNA is the result of inflammation rather than a unique IBD-related abnormality. Gastroenterology (1997) 112: A998.
122. Böcker U, Damiao A, Holt L et al, Expression of IL-1 receptor antagonist (IL-1RA) isophorms in human intestinal epithelial cells from the normal and inflamed bowel. Gastroenterology (1997) 112: A938.
123. Cominelli F, Nast CC, Clark BD et al, Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest (1990) 86: 972-80.
124. Carter DB, Deibel MR Jr, Dunn CJ et al, Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature (1990) 344: 633-8.
125. Thomas TK, Will PC, Srivastava A et al, Evaluation of an interleukin-1 receptor antagonist in the rat acetic acid-induced colitis model. Agents Action (1991) 34: 187-90.
126. Cominelli F, Nast CC, Duchini A, Lee M, Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology (1992) 103: 65-71.
127. Ferretti M, Casini-Raggi V, Pizarro TT et al, Neutralization of endogenous interleukin-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest (1994) 94: 449-53
128. Rennick D, Davidson N, Berg D, Interleukin-10 gene knock-out mice: a model of chronic inflammation. Clin Immunol Immunopathol (1995) 76: S174-8.
129. Kuhn R, Lohier J, Rennick D et al, Interleukin-10 deficient mice develop chronic enterocolitis. Cell (1993) 75: 263-74.
130. + Th1-like responses. J Clin Invest (1996) 98: 1010-20.
131. Herfarth H, Janardhanam R, Rath HC, Sartor RB, In vivo IL-10 treatment suppresses experimental chronic granulomatous inflammation and has an additive effect with corticosteroids. Gastroenterology (1996) 110: A924.
132. Schreiber S, Heinig T, Thiele HG, Raedler A, Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology (1995) 108: 1434-44.
133. Powrie F, Leach MW, Mauze S et al, Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C.B-17 scid mice. Int Immunol (1993) 5: 1461-71.
134. Powrie F, T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity (1995) 3: 171-4.
135. Barbara G, Hogaboam CM, Gauldie J, Collins SM, Interleukin-10 gene therapy prevents the occurrence but doesn't reverse experimental colitis. Gastroenterology (1997) 112: A927.
136. Duchmann R, Schmitt E, Knolle P et al, Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Gastroenterology (1996) 110: A889.
137. Madsen KL, Tavernini MM, Doyle JSG, Fedorak RN, Lactobacillus species prevents development of enterocolitis in interleukin-10 gene-deficient mice. Gastroenterology (1997) 112: A1030.
138. Gray DJ, Madsen KL, Tavernini MM et al, Interleukin-10 gene-deficient mice have a primary intestinal permeability defect prior to the development of enterocolitis. Gastroenterology (1997) 112: A984.
139. van Deventer SJH, Elson CO, Fedorak RN and the IL-10/IBD Cooperative Study Group, Safety, tolerance, pharmacokinetics and pharmaco-dynamics of recombinant interleukin (SCH 52000) in patients with steroid refractory Crohn's disease. Gastroenterology (1996) 110: A1034.
140. Nielsen OH, Køppen T, Rüdiger N et al, Involvement of interleukin-4 and -10 in inflammatory bowel disease. Dig Dis Sci (1996) 41: 1786-93.
141. Qui BS, Pfeiffer CJ, Keith JC, Protection by recombinant human interleukin-11 against experimental TNB-induced colins in rats. Dig Dis Sci (1996) 41: 1625-30.
142. Albert LM, Soley E, Ingram R et al, Luminal colonic treatment with recombinant human interleukin-11 decreases bowel lesions in HLA-B27 transgenic rats. Gastroenterology (1997) 112: A920.
143. Bank S, Sninsky C, Robinson M et al, Safety and activity evaluation of rhIL-11 in subjects with active Crohn's disease. Gastroenterology (1997) 112: A927.
144. Plevy SE, Targan SR, Yang H et al, Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6. Gastroenterology (1996) 110: 1053-60.
145. Forcione DG, Sands B, Isselbacher KJ et al, An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allelle. Proc Natl Acad Sci USA (1996) 93: 5094-8.
146. Masuda H, Nakamura Y, Tanaka T, Hayakawa S, Distinct relationship between HLA-DR genes and intractability of ulcerative colitis. Am J Gastroenterol (1994) 89: 957-62.
147. Stokkers PCF, Camoglio L, van Deventer SJH, Tumor necrosis factor (TNF) in inflammatory bowel disease: gene polymorphisms, animal models, and potential for anti-TNF therapy. J Inflammation (1996) 47: 97-103.
148. Braegger CP, Nicholis S, Murch SH et al, Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet (1992) 339: 89-91.
149. van Dullemen HM, van Deventer SJH, Hommes DA et al, Treatment of Crohn's disease with antitumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 109: 129-35.
150. Scallon BJ, Moore MA, Trinh H et al, Chimeric anti-TNF-α monoclonal antibody, cA2, binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine (1995) 7: 251-9.
151. Plevy SE, Taylor K, DeWoody KL et al, Tumor necrosis factor (TNF) microsatellite haplotypes and perinuclear anti-neutrophil cytoplasmic antibody identify Crohn's disease patients with poor clinical responses to anti-TNF monoclonal antibody. Gastroenterology (1997) 112: A1062.
152. McCabe RP, Woody J, van Deventer S et al, A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease. Gastroenterology (1996) 110: A962.
153. Targan SR, Rutgeerts P, Hanauer SB et al and the Crohn's Disease cA2 Study Group, A multicenter trial of anti-tumor necrosis factor antibody for treatment of patients with active Crohn's disease. Gastroenterology (1996) 110: A1026.
154. Rutgeerts P, D'Haens G, van Deventer SJH et al and the Crohn's Disease cA2 Study Group. Retreatment with anti-TNF-α chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease. Gastroenterology (1997) 112: A1078.
155. Elliott MJ, Maini RN, Feldmann M et al, Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344: 1105-10.
156. Sands BE, Podolsky DK, Tremaine WJ et al, Chimeric monoclonal anti-tumor necrosis factor antibody in the treatment of severe, steroid-refractory ulcerative colitis. Gastroenterology (1996) 110: A1008.
157. Evans RC, Clark L, Heath P, Rhodes JM, Treatment of ulcerative colitis with an engineered human anti-TNF-alpha antibody CDP571. Gastroenterology (1996) 110: A905.
158. Stack WA, Mann SD, Roy AJ et al, Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet (1997) 349: 521-4.
159. Bauditz J, Haemling J, Ortner M et al, Treatment with tumour necrosis factor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut (1997) 40: 470-4.
160. van Deventer SJH, Tumour necrosis factor and Crohn's disease. Gut (1997) 40: 443-8.
161. Moss ML, Catherine Jin S-L, Milla ME et al, Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature (1997) 385: 733-6.
162. Editorial, Glaxo Wellcome breaking new ground. Scrip (1997) 2232: 22.
163. Casini-Raggi V, Monsacchi L, Vosbeck K et al, Anti-inflammatory effects of CGP 47969A, a novel inhibitor of proinflammatory cytokine synthesis, in rabbit immune colitis. Gastroenterology (1995) 109: 812-18.
164. Williams RO, Mason LJ, Feldmann M, Maini RN, Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA (1994) 91: 2762-6.
165. Hsieh CS, Macatonia SE, Tripp CS et al, Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science (1993) 260: 496-7.
166. Macatonia SE, Hosken NA, Litton M et al, Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T-cells. J Immunol (1995) 154: 5071-9.
167. Trembleau S, Penna G, Bosi E et al, Interleukin-12 administration induces T helper 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med (1995) 181: 817-21.
168. Leonard JP, Walderburger KE, Goldman SJ, Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin-12. J Exp Med (1995) 181: 381-6.
169. Monteleone G, Biancone L, Marasco R et al, Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology (1997) 112: 1169-78.
170. Neurath MF, Fuss I, Kelsall BL et al, Antibodies to interleukin-12 abrogate established experimental colitis in mice. J Exp Med (1995) 182: 1281-90.
171. Grabstein KH, Eisenman J, Shanebeck K et al, Clonin of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science (1994) 264: 965-8.
172. Armitage RJ, Macduff BM, Eisenman J et al, IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol (1995) 154: 483-90.
173. Seder RA, High-dose IL-2 and IL-15 enhance the in vitro priming of naive CD4+ T cells for IFN-gamma but have differential effects on priming for IL-4. J Immunol (1996) 156: 2413-22.
174. Mori A, Suko M, Kaminuma O et al, IL-15 promotes cytokine production of human T helper cells. J Immunol (1996) 156: 2400-5.
175. Wilkinson PC, Liew FY, Chemoattraction of human blood T lymphocytes by interleukin-15. J Exp Med (1995) 181: 1255-9.
176. Nieto M, del Pozo MA, Sanchez-Madrid F, Interleukin-15 induces adhesion receptor redistribution in T lymphocytes. Eur J Immunol (1996) 62: 543-5.
177. Doherty TM, Seder RA, Sher A, Induction and regulation of IL-15 expression in murine macrophages. J Immunol (1996) 156: 735-41.
178. Mclnnes IB, al-Mughales J, Field M et al, The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nature Med (1996) 2: 175-82.
179. Agostini C, Trentin L, Facco M et al, Role of IL-15, IL-2 and their receptors in the development of T cell alveloitis in pulmonary sarcoidosis. J Immunol (1996) 157: 910-18.
180. Kirman I, Nielsen OH, Increased numbers of interleukin-15 expressing cells in active ulcerative colitis. Am J Gastroenterol (1996) 91: 7189-94.
181. Treiber-Held S, Stewart DM, Kurman CC, Nelson DL, IL-15 induces the release of soluble IL-2R alpha from human peripheral blood mononuclear cells. Clin Immunol Immunopathol (1996) 79: 71-8.
182. Treiber-Held S, Stewart DM, Barraclough HA et al, Release of sIL-2R alpha from and activation of native human peripheral blood mononuclear cells by recombinant IL-15. Clin Immunol Immunopathol (1996) 80: 67-75.
183. Cosman D, Kumaki S, Ahdieh M et al, Interleukin 15 and its receptor. Ciba Found Symp (1995) 195: 221-9.
184. Stevens AC, Maslinski W, Bitton A et al, Interleukin 15 mRNA transcripts in ulcerative colitis colonic specimens. Gastroenterology (1995) 108: A923.